Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03883360
Other study ID # HP-00082213
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date January 2050
Est. completion date March 2050

Study information

Verified date April 2021
Source University of Maryland, Baltimore
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A large proportion of people with a schizophrenia-spectrum disorder, especially in the early stages of the disease, regularly consume cannabis. Cannabis use is associated with poor prognostic outcome; however, there are no effective interventions targeted at reducing cannabis use or its deleterious effects in this population. The present trial is designed to test whether cannabidiol (CBD), a cannabinoid whose effects are in many ways antagonistic to those of Δ9-tetrahydrocannabinol (THC), can reduce psychiatric symptoms, cognitive deficits, and cannabis use in people with recent-onset psychosis who regularly consume cannabis.


Description:

This is a double-blind, randomized, placebo-controlled trial, evaluating the effects of a 12-week treatment course with CBD on psychiatric symptoms, cognition, and cannabis consumption in regular cannabis users with recent-onset psychosis. The study will be conducted at the Maryland Psychiatric Research Center (University of Maryland School of Medicine) and associated Early Intervention Programs in Baltimore, at the Sheppard Pratt Health System in Baltimore, and at the Psychosis Clinic of the University of California Los Angeles. The daily dose of CBD is 600 mg (p.o.), administered as adjunct medication. Any non-exclusionary antipsychotic, antidepressant, anxiolytic, or other medication prescribed prior to the trial will be continued. Participants may, but do not have to be taking conventional antipsychotic medication. The study will include 84 regular cannabis users with a schizophrenia-spectrum disorder who experienced their first psychotic episode within the last 5 years (90). Participants will be randomized 1:1 to either the CBD or the placebo group. Outcome measures include psychiatric symptoms, cognition, global functioning, and drug use, and will be assessed at baseline, and every 3 or 6 weeks thereafter (depending on the measure), until the end of treatment at 12 weeks. Outcome will be assessed again at a 3-month follow-up.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date March 2050
Est. primary completion date February 2050
Accepts healthy volunteers No
Gender All
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: - DSM-5 diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, and other specified or unspecified schizophrenia spectrum and other psychotic disorder. - Experienced a first psychotic episode within the last 5 years. - Self-reported cannabis use at least twice/week for at least the last 4 weeks. - THCCOOH serum levels of = 5 ng/mL. - Total score =45 on the 18-item version of the Brief Psychiatric Rating Scale. - Able to give written informed consent. - Normal or corrected to normal vision. - If medicated, no change in psychiatric medication within the preceding 4 weeks, with no foreseeable changes. Exclusion Criteria: - DSM-5 diagnosis of Substance Use Disorder other that cannabis or nicotine within the last year (recreational use is not exclusionary). - Currently undergoing active treatment for Cannabis Use Disorder other than low-level (once/week or less) psychosocial intervention. - Uncontrolled hypertension (resting systolic BP above 150 or diastolic above 95 mm Hg). - Cardiovascular disease, such as history of myocardial infarction and ischemia, heart failure, angina, severe arrhythmias, or EKG abnormalities (Wolf-Parkinson-White syndrome, Complete left bundle branch block, PR interval <120 ms or >200 ms, Prolonged QT interval (corrected) >500 ms, Cardiac arrhythmias as defined by PACs >3 per min or PVCs >1 per min). - History of or current neurological illness, such as stroke, seizure disorders, neurodegenerative diseases, or organic brain syndrome. - Intellectual disability. - Pregnant or lactating. - Diabetes. - Significant kidney or liver impairment. - Any chronic or severe infectious disease, including HIV and hepatitis. - Cancer. - Use of any barbiturates, diazepam, diltiazem, verapamil, protease inhibitors, any anticonvulsant medications (including valproate/valproic acid, lamotrigine, carbamazepine, and clobazam), glipizide, glyburide, warfarin, and cyclophosphamide/ ifosfamide, due to potential interaction with CBD at the metabolic level. - Suicidal ideation currently or within last 6 months (score of >/= 3 on the Columbia Suicide Severity Rating Scale). - Less than the lower limit of normal hemoglobin and hematocrit at screening. - Elevated transaminase levels >3 times the ULN, accompanied by elevations in bilirubin >2 times the ULN.

Study Design


Intervention

Drug:
Cannabidiol (CBD)
Participants receive a single dose of CBD (600 mg p.o.) per day for 12 weeks.
Placebo
Participants receive a single daily dose of the oil vehicle used to dissolve CBD but without any active ingredient, in the same amount as the CBD group, for 12 weeks.

Locations

Country Name City State
United States Sheppard Pratt Health System Baltimore Maryland
United States Maryland Psychiatric Research Center Catonsville Maryland
United States Semel Institute for Neuroscience and Human Behavior Los Angeles California

Sponsors (3)

Lead Sponsor Collaborator
University of Maryland, Baltimore Sheppard Pratt Health System, University of California, Los Angeles

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in Negative Symptom Assessment (NSA-16) - exploratory The 16-item Negative Symptom Assessment (NSA-16) is a validated and widely used scale capturing different facets of negative symptoms. Each item is scored on a scale of 1 to 6, and the total score is derived by adding individual item scores. Larger values represent worse symptoms. Baseline and 12 weeks
Primary Change in Brief Psychiatric Rating Scale (BPRS) total score The BPRS consists of 18 items assessing a broad range of psychiatric symptoms, including positive, negative, and affective symptoms. Each item is scored 1-7. Total scores are the sum of all items and range from 18 to 126, with larger values reflecting worse symptoms. The BPRS total score has been used widely in clinical studies of psychosis and has demonstrated reliability in assessing psychopathology across diverse psychosis populations. Baseline and 12 weeks
Primary Change in MATRICS Consensus Cognitive Battery (MCCB) composite score The MCCB is an FDA-approved assessment tool for trials of cognition-enhancing treatments in people with schizophrenia. The MCCB is comprised of the following domains: 1) Speed of Processing; 2) Attention/Vigilance; 3) Working Memory; 4) Verbal Learning; 5) Visual Learning; 6) Reasoning and Problem Solving; and 7) Social Cognition. The composite score is standardized to a T-scale (mean=50, standard deviation=10) based on healthy control normative data. Higher scores reflect better performance. Baseline and 12 weeks
Primary Change in Serum concentrations of THCCOOH THCCOOH is a THC metabolite and is used to quantify cannabis consumption. It has a long half-life (5-6 days) and thus provides a summary index of cannabis use within the last 1-2 weeks. Baseline and 12 weeks
Secondary Change in BPRS positive symptoms The average of four BPRS key positive symptom items (conceptual disorganization, suspiciousness, unusual thought content, and hallucinatory behavior) will be analyzed as an index of antipsychotic effects of CBD. Possible values range from 1 to 7, with larger values reflecting more severe positive symptoms. Baseline and 12 weeks
Secondary Change in BPRS "Anxiety/Depression" subscale This subscale will be analyzed separately to obtain an index of the anxiolytic effects of CBD. Possible values range from 1 to 7, with larger values reflecting more anxiety/depression. Baseline and 12 weeks
Secondary Change in State-Trait Anxiety Inventory (STAI) - State version The STAI-State provides another probe for potential anxiolytic effects of CBD. The participant rates 20 items about how they feel right now and a scale from 1 (not at all) to 4 (very much so). The total score is derived by adding all values and ranges from 20 to 80, with larger values indicating greater anxiety. Baseline and 12 weeks
Secondary Change in MCCB Processing Speed subscale The score is standardized to a T-scale (mean=50, standard deviation=10) based on healthy control normative data. Higher scores reflect better performance. Baseline and 12 weeks
Secondary Change in MCCB Attention/Vigilance subscale The score is standardized to a T-scale (mean=50, standard deviation=10) based on healthy control normative data. Higher scores reflect better performance. Baseline and 12 weeks
Secondary Change in MCCB Working Memory subscale The score is standardized to a T-scale (mean=50, standard deviation=10) based on healthy control normative data. Higher scores reflect better performance. Baseline and 12 weeks
Secondary Change in MCCB Verbal Learning subscale The score is standardized to a T-scale (mean=50, standard deviation=10) based on healthy control normative data. Higher scores reflect better performance. Baseline and 12 weeks
Secondary Change in MCCB Visual Learning subscale The score is standardized to a T-scale (mean=50, standard deviation=10) based on healthy control normative data. Higher scores reflect better performance. Baseline and 12 weeks
Secondary Change in MCCB Reasoning/Problem solving subscale The score is standardized to a T-scale (mean=50, standard deviation=10) based on healthy control normative data. Higher scores reflect better performance. Baseline and 12 weeks
Secondary Change in MCCB Social Cognition subscale The score is standardized to a T-scale (mean=50, standard deviation=10) based on healthy control normative data. Higher scores reflect better performance. Baseline and 12 weeks
Secondary Change in The UCSD Performance-Based Skills Assessment (UPSA) Measures ability to perform real-life tasks by standardized role-play. Scores reflect percent correct, i.e. range from 0-100, with larger scores reflecting better performance. Baseline and 12 weeks
Secondary Change in Serum concentrations of THC Index of recent cannabis use. Baseline and 12 weeks
Secondary Change in Self-reported days of cannabis use The reference period is the last three weeks. Thus, possible values range from 0 to 21. Baseline and 12 weeks
Secondary Change in Cannabis Use Disorders Identification Test-Revised (CUDIT-R) The CUDIT-R is an 8-item questionnaire probing cannabis use frequency, amount, loss of control, and adverse consequences in the last 6 months. Each item is rated on a scale from 0 to 4. The total score is derived by summing all answers and ranges from 0 to 32, with larger values representing greater use severity. Baseline and 12 weeks
Secondary Change in Specific Levels of Functioning scale (SLOF) An index of real-world, everyday functioning, derived by summing 30 item scores (1-5). Higher scores reflect better functioning. Baseline and 12 weeks
Secondary Change in Behavior And Symptom Identification Scale (BASIS) - revised A self-report questionnaire to assess mental health treatment outcomes. Only the first 24 items (probing daily life functioning, social behavior, and mood) are included, each scored on a scale from 0 to 4. The total score is derived by summing individual item scores are re-poling some items, with larger values representing worse outcome. Baseline and 12 weeks
Secondary Change in Serum concentrations of CBD To confirm bioavailability of the study drug. Baseline and 12 weeks
Secondary Change in Serum concentrations of anandamide Anandamide is an endocannabinoid that has been reported to be down-regulated by cannabis use and up-regulated by CBD. Baseline and 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT03253926 - Effect of Lorcaserin on Cannabis Withdrawal and Self-administration Phase 1/Phase 2
Completed NCT04060602 - Personalized Feedback Intervention to Reduce Risky Cannabis Use. N/A
Completed NCT01212081 - Assessment of Cannabis Craving in Schizophrenia Using Virtual Reality
Recruiting NCT04988490 - Quantification of Cannabinoids and Comparison to Post-Surgical Pain Medication Requirements and Surgical Outcomes
Recruiting NCT05188404 - Aging and Marijuana: Benefits, Effects, and Risks
Completed NCT03662737 - VRT as a Biomarker of Cerebellar Dysfunction in Chronic Cannabis Use
Not yet recruiting NCT05999383 - Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration Phase 2
Terminated NCT04436055 - Intergenerational Effects of Paternal Periconceptional Cannabis and Other Drug Use (EPIC)
Active, not recruiting NCT04374773 - Effects of Pregnancy-associated Hormones on THC Metabolism in Women Phase 4
Completed NCT04316741 - Brief Intervention Combined With Health Coaching Via Social Media for Cannabis Use N/A
Recruiting NCT05396638 - Characterization of Endocannabinoid and Endogenous Opioid Levels in Adolescents With Cannabis Use Disorder N/A
Recruiting NCT05309226 - Cannabis Use in Pregnancy and Downstream Effects on Maternal and Infant Health
Recruiting NCT03859089 - Cannabis for Opioid Substitution Trial
Recruiting NCT05849636 - Alerta Cannabis: Evaluation of Web-based Tailored Intervention N/A
Enrolling by invitation NCT05521321 - Feasibility and Acceptability of the Cannabis Awareness and Prevention Toolkit N/A
Recruiting NCT05119244 - Environment and Lung Cancer N/A
Recruiting NCT04841655 - Tobacco Cessation Among Smokers Under Alcohol and/or Cannabis Treatment
Terminated NCT04100590 - Eye Tracking as a Biomarker of Cannabis Effects Phase 2
Completed NCT05167097 - Mindsets and the Effectiveness of a Brief Intervention - Replication N/A
Recruiting NCT04114903 - Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity